CD8A and neoplasm: Another method [14] is to enrich tumour-reactive T cells from a heterogeneous TILs population, the CD8+ PD-1+ 4-1BB+ TILs population, followed by direct reprogramming into induced pluripotent stem cells (iPSCs), enabling them to be enhanced for more potent ACT.